244 related articles for article (PubMed ID: 31766386)
1. mTOR Links Tumor Immunity and Bone Metabolism: What are the Clinical Implications?
Irelli A; Sirufo MM; Scipioni T; De Pietro F; Pancotti A; Ginaldi L; De Martinis M
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31766386
[TBL] [Abstract][Full Text] [Related]
2. Role of mTOR Signaling in Tumor Microenvironment: An Overview.
Conciatori F; Bazzichetto C; Falcone I; Pilotto S; Bria E; Cognetti F; Milella M; Ciuffreda L
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30126252
[TBL] [Abstract][Full Text] [Related]
3. mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment.
Mafi S; Mansoori B; Taeb S; Sadeghi H; Abbasi R; Cho WC; Rostamzadeh D
Front Immunol; 2021; 12():774103. PubMed ID: 35250965
[TBL] [Abstract][Full Text] [Related]
4. The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations.
Collins DC; Chenard-Poirier M; Lopez JS
Curr Cancer Drug Targets; 2018; 18(4):355-364. PubMed ID: 28969535
[TBL] [Abstract][Full Text] [Related]
5. PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways.
Wu DD; Gao YR; Li T; Wang DY; Lu D; Liu SY; Hong Y; Ning HB; Liu JP; Shang J; Shi JF; Wei JS; Ji XY
BMC Cancer; 2018 May; 18(1):499. PubMed ID: 29716528
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
7. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
8. Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Sun H; Yin M; Qian W; Yin H
Med Sci Monit; 2018 Sep; 24():6178-6186. PubMed ID: 30182951
[TBL] [Abstract][Full Text] [Related]
9. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
[TBL] [Abstract][Full Text] [Related]
10. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
11. Neuroinflammation and central PI3K/Akt/mTOR signal pathway contribute to bone cancer pain.
Zhang J; Wang L; Wang H; Su Z; Pang X
Mol Pain; 2019; 15():1744806919830240. PubMed ID: 30717619
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
13. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway.
Viel S; Marçais A; Guimaraes FS; Loftus R; Rabilloud J; Grau M; Degouve S; Djebali S; Sanlaville A; Charrier E; Bienvenu J; Marie JC; Caux C; Marvel J; Town L; Huntington ND; Bartholin L; Finlay D; Smyth MJ; Walzer T
Sci Signal; 2016 Feb; 9(415):ra19. PubMed ID: 26884601
[TBL] [Abstract][Full Text] [Related]
14. Anti-proliferative effect of RCE-4 from Reineckia carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-κB activation.
Bai C; Yang X; Zou K; He H; Wang J; Qin H; Yu X; Liu C; Zheng J; Cheng F; Chen J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):573-84. PubMed ID: 26935715
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor efficacy of phellamurin in osteosarcoma cells: Involvement of the PI3K/AKT/mTOR pathway.
Zhang H; Jiang H; Zhang H; Liu J; Hu X; Chen L
Eur J Pharmacol; 2019 Sep; 858():172477. PubMed ID: 31228450
[TBL] [Abstract][Full Text] [Related]
16. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death-1 Inhibition of Phosphatidylinositol 3-Kinase/AKT/Mechanistic Target of Rapamycin Signaling Impairs Sarcoidosis CD4
Celada LJ; Rotsinger JE; Young A; Shaginurova G; Shelton D; Hawkins C; Drake WP
Am J Respir Cell Mol Biol; 2017 Jan; 56(1):74-82. PubMed ID: 27564547
[TBL] [Abstract][Full Text] [Related]
18. Differential Phosphatidylinositol-3-Kinase-Akt-mTOR Activation by Semliki Forest and Chikungunya Viruses Is Dependent on nsP3 and Connected to Replication Complex Internalization.
Thaa B; Biasiotto R; Eng K; Neuvonen M; Götte B; Rheinemann L; Mutso M; Utt A; Varghese F; Balistreri G; Merits A; Ahola T; McInerney GM
J Virol; 2015 Nov; 89(22):11420-37. PubMed ID: 26339054
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-133a alleviates airway remodeling in asthtama through PI3K/AKT/mTOR signaling pathway by targeting IGF1R.
Shao Y; Chong L; Lin P; Li H; Zhu L; Wu Q; Li C
J Cell Physiol; 2019 Apr; 234(4):4068-4080. PubMed ID: 30146725
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
